TGFB1 and diabetic kidney disease: A recent double blind phase II study assessed whether modulating TGF-β1 activity with a TGF-β1-specific, humanized, neutralizing monoclonal antibody was effective in slowing renal function loss in patients with diabetic nephropathy on RAAS inhibition treatment over a 12-month period.